Today's Daily Dose brings you news about Neurocrine Biosciences' upcoming regulatory catalyst; Celgene's RADIANCE Part B trial results; tentative approval of Eagle Pharma's cancer drug Pemfexy; trial results of Kura's preclinical drug candidate, KO-539, and phase II drug candidate Tipifarnib.
Original Article: FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch
NEXT ARTICLE